Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Early prediction of pathological complete response in luminal B type neoadjuvant chemotherapy-treated breast cancer patients: comparison between interim F-18-FDG PET/CT and MRI

Authors
Pahk, KisooKim, SungeunChoe, Jae Gol
Issue Date
9월-2015
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Keywords
breast cancer; F-18-FDG PET; luminal B type; MRI; neoadjuvant chemotherapy; PET/CT; response
Citation
NUCLEAR MEDICINE COMMUNICATIONS, v.36, no.9, pp.887 - 891
Indexed
SCIE
SCOPUS
Journal Title
NUCLEAR MEDICINE COMMUNICATIONS
Volume
36
Number
9
Start Page
887
End Page
891
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/92588
DOI
10.1097/MNM.0000000000000329
ISSN
0143-3636
Abstract
PurposeThe aim of this study is to justify the effectiveness of interim PET/computed tomography (CT) for predicting pathological complete response (pCR) in luminal B type breast cancer patients and to compare the diagnostic performance of interim PET/CT and MRI.Materials and methodsTwenty-one patients with neoadjuvant chemotherapy (NAC)-treated luminal B type breast cancer were included. All patients underwent PET/CT and MRI at baseline and interim (mid-point). Breast surgery was performed after completion of NAC. Maximum standardized uptake values (SUVmax) of breast malignant lesions in each PET/CT scan were acquired in each patient. The metabolic response was calculated as follows: SUV (%)=(baseline SUVmax-interim SUVmax)/baseline SUV(max)x100 (%). In MRI, the relative size change was calculated as follows: Size change (%)=longest diameter interim MRI-longest diameter baseline MRI/longest diameter baseline MRIx100 (%). pCR was concluded through the final pathologic specimen after breast surgery. The receiver-operating characteristic analysis was used as a statistical method.ResultsOf 21 patients, seven achieved a pCR after surgery. In PET/CT, an optimal cut-off SUV (%) of 69.0% was proposed with a sensitivity of 85.7% and a specificity of 100% (P<0.0001). In MRI, an optimal cut-off size change (%) was 38.2% with a sensitivity of 64.3% and a specificity of 71.4% (P=0.29). The area under the curve was 0.92 and 0.65, respectively. PET/CT presented better predictability of the pCR than MRI (P=0.04).ConclusionIn luminal B type NAC-treated breast cancer patients, it is possible to use PET/CT as an early surrogate marker for predicting pCR and it is significantly more predictable for pCR than MRI. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kim, Sung eun photo

Kim, Sung eun
의과대학 (의학과)
Read more

Altmetrics

Total Views & Downloads

BROWSE